Abstract
Management of patent ductus arteriosus (PDA) in preterm newborns has been debated extensively for more than six decades. Some authors affirm that PDA is only an innocent mirror of infant immaturity, without specific health consequences. They also underline the futility, even danger, of treating it. Others are concerned about the hemodynamic effects of this left-right shunt, resulting in high pulmonary blood flow and low systemic output, which can contribute to the occurrence of severe morbidities — including pulmonary hemorrhage, intraventricular hemorrhage, bronchopulmonary dysplasia and necrotizing enterocolitis —and may increase the risk of death. Many management strategies have been described, ranging from expectant management to nontargeted prophylaxis, but there is currently no consensus about who to treat, when, and how.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
